• NeuroOne secured its first pharmaceutical industry purchase order for StereoCED to support a Tier 1 global pharmaceutical company's preclinical research program.
• The large-animal study is expected to begin early next year, using the platform's targeted brain drug delivery and neurological monitoring capabilities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neuroone Medical Technologies Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610220831PRIMZONEFULLFEED9851162) on October 22, 2026, and is solely responsible for the information contained therein.